BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Reference Citation Analysis]
2 Gu X, Zhou W, Han J, Algalil FA. Factors Affecting the Readmission of Patients with Pancreatic Cancer after Surgery. Applied Bionics and Biomechanics 2022;2022:1-6. [DOI: 10.1155/2022/6106914] [Reference Citation Analysis]
3 Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, Tachibana T, Shinada M, Zhang M, Kurosawa G, Sugyo A, Tsuji AB, Higashi T, Kurihara H, Ueno M, Yoshii Y. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. IJMS 2022;23:5807. [DOI: 10.3390/ijms23105807] [Reference Citation Analysis]